Siga Monkeypox Antiviral to Undergo First Human Tests in UK
- Researchers see Tpoxx as most promising drug candidate
- Trial will enroll 500 and hopes to have result by Christmas
A bottle of Tecovirimat.
Photographer: Yuki Iwamura/AFP/Getty Images
This article is for subscribers only.
Follow us at @BloombergUK and on Facebook, and wrap up your day with The Readout newsletter with Allegra Stratton.
Siga Technologies Inc.’s antiviral Tpoxx, which has mainly been shown to fight monkeypox in animal studies, will undergo human testing by University of Oxford researchers as countries look for ways to tackle a growing outbreak with limited vaccine supply.